United Therapeutics Corporation with ticker code (UTHR) have now 11 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between 375 and 160 calculating the mean target price we have $281.18. Now with the previous closing price of $218.59 this would imply there is now a potential upside of 28.6%. There is a 50 day moving average of $221.63 while the 200 day moving average is $238.47. The company has a market capitalization of 10.13B. The stock price for Iron Mountain Incorporated is 216.19 USD
The potential market cap would be $13,029,899,157 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 14.75, revenue per share of 43.28 and a 10.52% return on assets.
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso and Tyvaso DPI are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKinds Afrezza (insulin human) Inhalation Powder product.
